Loading the stock brief
Stock brief · the live tape
RVMDRevolution Medicines, Inc.
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · Nasdaq
$189.76
▼ $17.92 (-8.6%) · 30dclose Friday, October 9, 2026
No member of Congress has disclosed a trade in this ticker.
405 insider filings · 5 tracked funds
The Hillno disclosed congressional trade
The Boardroom
▲ 2▼ 218
2 buys · 218 sells · 405 filingsFeeding Time
▲ 5▼ 0
5 adding · 0 trimming · 5 holdingCAT Scan
52Quiet, routine or stale filings, or buying and selling that cancel out.
- Funds▲2 tracked funds bought or added, latest 14 Aug
- Insiders·1 insider sold in the open market, latest 25 Aug
- Congress·Nothing counted in the last year
Quiet since 25 Aug
Scored 15 Oct · From public filings. Not a forecast. How it works
The tape
Price with a twin dot per disclosed trade: filled at the trade, hollow at the filing. The dashed gap is what the market did in between, not anyone’s return.
trade (insider)
The boardroom
Scheduled 10b5-1 sales are usually noise, set on autopilot months ago. The unscheduled ones are the ones to read.
Sandler Alan B.Chief Development OfficerScheduled · 10b5-1
Sandler Alan B.Chief Development OfficerScheduled · 10b5-1
Sandler Alan B.Chief Development OfficerScheduled · 10b5-1
Sandler Alan B.Chief Development OfficerScheduled · 10b5-1
Sandler Alan B.Chief Development OfficerScheduled · 10b5-1
Sandler Alan B.Chief Development OfficerScheduled · 10b5-1
Sandler Alan B.Chief Development OfficerScheduled · 10b5-1
Cislini JeffSVP & General CounselScheduled · 10b5-1
Mancini AnthonySee RemarksScheduled · 10b5-1
Mancini AnthonySee RemarksScheduled · 10b5-1
Mancini AnthonySee RemarksScheduled · 10b5-1
Mancini AnthonySee RemarksScheduled · 10b5-1
ANDERSON ELIZABETH MDirectorScheduled · 10b5-1
ANDERSON ELIZABETH MDirectorScheduled · 10b5-1
ANDERSON ELIZABETH MDirectorScheduled · 10b5-1
ANDERSON ELIZABETH MDirectorScheduled · 10b5-1
ANDERSON ELIZABETH MDirectorScheduled · 10b5-1
ANDERSON ELIZABETH MDirectorScheduled · 10b5-1
ANDERSON ELIZABETH MDirectorScheduled · 10b5-1
Mancini AnthonySee RemarksScheduled · 10b5-1
Anders JackChief Financial OfficerScheduled · 10b5-1
Cislini JeffSVP & General CounselScheduled · 10b5-1
Anders JackChief Financial OfficerScheduled · 10b5-1
GOLDSMITH MARK ASee Remarks, DirectorScheduled · 10b5-1
Horn Margaret AChief Operating OfficerScheduled · 10b5-1
Sandler Alan B.Chief Development OfficerScheduled · 10b5-1
Horn Margaret AChief Operating OfficerScheduled · 10b5-1
GOLDSMITH MARK ASee Remarks, DirectorScheduled · 10b5-1
Kelsey Stephen MichaelSee RemarksScheduled · 10b5-1
Mancini AnthonySee RemarksScheduled · 10b5-1
Mancini AnthonySee RemarksScheduled · 10b5-1
Sandler Alan B.Chief Development OfficerScheduled · 10b5-1
Kelsey Stephen MichaelSee RemarksScheduled · 10b5-1
Cislini JeffSVP & General CounselScheduled · 10b5-1
Kelsey Stephen MichaelSee RemarksScheduled · 10b5-1
Kelsey Stephen MichaelSee RemarksScheduled · 10b5-1
Kelsey Stephen MichaelSee RemarksScheduled · 10b5-1
Kelsey Stephen MichaelSee RemarksScheduled · 10b5-1
Kelsey Stephen MichaelSee RemarksScheduled · 10b5-1
Kelsey Stephen MichaelSee RemarksScheduled · 10b5-1
The fund book
Tracked 13F holders and how their position moved, quarter over quarter.
Baker Bros. Advisors LP$2.1B11.4M sharesaddedCitadel Advisors LLC$110.5M590K sharesaddedDuquesne Family Office$74.8M400K sharesaddedBaillie Gifford & Co$49.3M263K sharesaddedPoint72 Asset Management$11.3M60K sharesnew position
Positions as filed for the quarter ending 30 Jun 2026, the latest on file. A 13F is a quarter-end photograph filed up to 45 days later, so this is where these funds stood then, not what they hold now. Common stock only: options and short positions are not in a 13F, and a fund that had already sold out does not appear.
⚠️ Public information, sourced from STOCK Act, Form 4 and 13F filings. Ranges use midpoints. Price paths between a trade and its filing are market moves, not anyone’s return. Not financial advice.